0001062993-22-022769.txt : 20221125
0001062993-22-022769.hdr.sgml : 20221125
20221125091134
ACCESSION NUMBER: 0001062993-22-022769
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20221125
DATE AS OF CHANGE: 20221125
EFFECTIVENESS DATE: 20221125
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Thiogenesis Therapeutics, Corp.
CENTRAL INDEX KEY: 0001877778
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 0228
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-465814
FILM NUMBER: 221418030
BUSINESS ADDRESS:
STREET 1: 4 KING STREET WEST, SUITE 401
CITY: TORONTO
STATE: A6
ZIP: M5H 1B6
BUSINESS PHONE: 6478467766
MAIL ADDRESS:
STREET 1: 4 KING STREET WEST, SUITE 401
CITY: TORONTO
STATE: A6
ZIP: M5H 1B6
FORMER COMPANY:
FORMER CONFORMED NAME: Rozdil Capital Corp
DATE OF NAME CHANGE: 20210810
D
1
primary_doc.xml
X0708
D
LIVE
0001877778
Thiogenesis Therapeutics, Corp.
4 KING STREET WEST, SUITE 401
TORONTO
A6
ONTARIO, CANADA
M5H 1B6
420 776659259
ONTARIO, CANADA
Rozdil Capital Corp
Corporation
true
2018
Brook
Riggins
4 King Street West, Suite 401
Toronto
A6
ONTARIO, CANADA
M5H 1B6
Executive Officer
Director
Patrice
Rioux
4 King Street West, Suite 401
Toronto
A6
ONTARIO, CANADA
M5H 1B6
Executive Officer
Director
Hogan
W.
Mullally
4 King Street West, Suite 401
Toronto
A6
ONTARIO, CANADA
M5H 1B6
Director
Kim
Tsuchimoto
4 King Street West, Suite 401
Toronto
A6
ONTARIO, CANADA
M5H 1B6
Director
Christopher
Starr
4 King Street West, Suite 401
Toronto
A6
ONTARIO, CANADA
M5H 1B6
Director
Other
Decline to Disclose
- 06b
false
2022-11-18
false
true
false
0
218303
218303
0
U.S. dollar amounts are based on the Bank of Canada exchange rate 0.7471 reported on November 18, 2022
false
3
0
0
0
false
Thiogenesis Therapeutics, Corp.
/s/ Brook G. Riggins
Brook G. Riggins
CFO
2022-11-25